Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade in Adults and Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Author(s): Ridhi Chhabra, Rachna Gupta and Lalit K. Gupta*

Volume 19, Issue 1, 2024

Published on: 18 April, 2023

Page: [33 - 43] Pages: 11

DOI: 10.2174/1574886318666230302124634

Price: $65

Abstract

Background: Cholinesterase inhibitors, such as neostigmine and edrophonium, commonly used to reverse the residual effects of nondepolarizing neuromuscular blocking drugs at the end of surgery are associated with a high rate of residual neuromuscular blockade (NMB). Due to its direct mechanism of action, sugammadex is associated with rapid and predictable reversal of deep NMB. The current analysis compares the clinical efficacy and risk of postoperative nausea and vomiting (PONV) on using sugammadex or neostigmine for routine NMB reversal in adult and pediatric populations.

Methods: PubMed and ScienceDirect were searched as the primary databases. Randomized controlled trials comparing sugammadex with neostigmine for routine NMB reversal in adult and pediatric patients have been included. The primary efficacy endpoint was the time from initiation of sugammadex or neostigmine to the recovery of a time-of-four ratio (TOF) ≥ 0.9. PONV events have been reported as secondary outcomes.

Results: A total of 26 studies have been included in this meta-analysis, 19 for adults with 1574 patients and 7 for children with 410 patients. Sugammadex, when compared to neostigmine, has been reported to take a shorter time to reverse NMB in adults (mean difference = -14.16 min; 95% CI [-16.88, -11.43], P < 0.01), as well as in children (mean difference = -26.36 min; 95% CI [- 40.16, -12.57], P < 0.01). Events of PONV have been found to be similar in both the groups in adults, but significantly lower in children treated with sugammadex, i.e., 7 out of 145 with sugammadex versus 35 out of 145 with neostigmine (odds ratio = 0.17; 95% CI [0.07, 0.40]).

Conclusion: Sugammadex is associated with a significantly shorter period of reversal from NMB in comparison to neostigmine in adult and pediatric patients. Regarding PONV, the use of sugammadex for NMB antagonism may offer a better option for pediatric patients.

Keywords: Cholinesterase inhibitors, neuromuscular blockade, pediatrics, post-operative nausea and vomiting, sugammadex, residual neuromuscular blockade.

« Previous Next »
Graphical Abstract

[1]
Wu X, Oerding H, Liu J, et al. Rocuronium blockade reversal with sugammadex vs neostigmine: Randomized study in Chinese and Caucasian subjects. BMC Anesthesiol 2014; 14(1): 53.
[http://dx.doi.org/10.1186/1471-2253-14-53] [PMID: 25187755]
[2]
Bowman WC. Neuromuscular block. Br J Pharmacol 2006; 147 (Suppl. 1): S277-86.
[http://dx.doi.org/10.1038/sj.bjp.0706404] [PMID: 16402115]
[3]
Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Libr 2017; 2017(9): CD012763.
[http://dx.doi.org/10.1002/14651858.CD012763] [PMID: 28806470]
[4]
Abola RE, Romeiser J, Rizwan S, Lung B, Gupta R, Bennett-Guerrero E. A randomized-controlled trial of sugammadex versus neostigmine: Impact on early postoperative strength. Can J Anaesth 2020; 67(8): 959-69.
[http://dx.doi.org/10.1007/s12630-020-01695-4] [PMID: 32405975]
[5]
Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia 2012; 67(9): 991-8.
[http://dx.doi.org/10.1111/j.1365-2044.2012.07197.x] [PMID: 22698066]
[6]
Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: A comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007; 104(3): 569-74.
[http://dx.doi.org/10.1213/01.ane.0000248224.42707.48] [PMID: 17312210]
[7]
van Vlymen JM, Parlow JL. The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. Anesth Analg 1997; 84(1): 148-54.
[http://dx.doi.org/10.1213/00000539-199701000-00027] [PMID: 8989016]
[8]
Fisher DM. Clinical pharmacology of neuromuscular blocking agents. Am J Health Syst Pharm 1999; 56(11 Suppl 1): S4-9.
[http://dx.doi.org/10.1093/ajhp/56.S4] [PMID: 10437710]
[9]
Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993; 3(4): 335-48.
[http://dx.doi.org/10.2165/00002512-199303040-00004] [PMID: 8369593]
[10]
Cappellini I, Picciafuochi F, Ostento D, Danti G, De Gaudio AR, Adembri C. Recovery of muscle function after deep neuromuscular block by means of diaphragm ultrasonography and adductor of pollicis acceleromyography with comparison of neostigmine vs sugammadex as reversal drugs: Study protocol for a randomized controlled trial. Trials 2018; 19(1): 135.
[http://dx.doi.org/10.1186/s13063-018-2525-7] [PMID: 29467022]
[11]
Fleming NW, Henderson TR, Dretchen KL. Mechanisms of respiratory failure produced by neostigmine and diisopropyl fluorophosphate. Eur J Pharmacol 1991; 195(1): 85-91.
[http://dx.doi.org/10.1016/0014-2999(91)90384-3] [PMID: 2065714]
[12]
Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2020; 131(2): 411-48.
[http://dx.doi.org/10.1213/ANE.0000000000004833] [PMID: 32467512]
[13]
Kenny GNC. Risk factors for postoperative nausea and vomiting. Anaesthesia 1994; 49 (Suppl. 1): 6-10.
[http://dx.doi.org/10.1111/j.1365-2044.1994.tb03576.x] [PMID: 8129161]
[14]
Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: An evidence-based review. Core Evid 2013; 8: 57-67.
[PMID: 24098155]
[15]
Gaszynski T, Szewczyk T, Gaszynski W. Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia. Br J Anaesth 2012; 108(2): 236-9.
[http://dx.doi.org/10.1093/bja/aer330] [PMID: 22012861]
[16]
Fuchs-Buder T, Meistelman C, Raft J. Sugammadex: Clinical development and practical use. Korean J Anesthesiol 2013; 65(6): 495-500.
[http://dx.doi.org/10.4097/kjae.2013.65.6.495] [PMID: 24427454]
[17]
Rex C, Wagner S, Spies C, et al. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia. Anesthesiology 2009; 111(1): 30-5.
[http://dx.doi.org/10.1097/ALN.0b013e3181a51cb0] [PMID: 19512873]
[18]
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372(71): n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[19]
Deana C, Barbariol F, D’Incà S, Pompei L, Rocca GD. SUGAMMADEX versus neostigmine after ROCURONIUM continuous infusion in patients undergoing liver transplantation. BMC Anesthesiol 2020; 20(1): 70.
[http://dx.doi.org/10.1186/s12871-020-00986-z] [PMID: 32213163]
[20]
Asztalos L, Szabó-Maák Z, Gajdos A, et al. Reversal of vecuronium-induced neuromuscular blockade with low-dose sugammadex at train-of-four count of four. Anesthesiology 2017; 127(3): 441-9.
[http://dx.doi.org/10.1097/ALN.0000000000001744] [PMID: 28640017]
[21]
Carron M, Veronese S, Foletto M, Ori C. Sugammadex allows fast-track bariatric surgery. Obes Surg 2013; 23(10): 1558-63.
[http://dx.doi.org/10.1007/s11695-013-0926-y] [PMID: 23519634]
[22]
Pongrácz A, Szatmári S, Nemes R, Fülesdi B, Tassonyi E. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation. Anesthesiology 2013; 119(1): 36-42.
[http://dx.doi.org/10.1097/ALN.0b013e318297ce95] [PMID: 23665915]
[23]
Adamus M, Hrabalek L, Wanek T, Gabrhelik T, Zapletalova J. Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. J Anesth 2011; 25(5): 716-20.
[http://dx.doi.org/10.1007/s00540-011-1209-1] [PMID: 21842171]
[24]
Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Álvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: A multicenter, randomized, controlled trial. Anesth Analg 2010; 110(1): 64-73.
[http://dx.doi.org/10.1213/ane.0b013e3181ac53c3] [PMID: 19713265]
[25]
Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: A randomized comparison with neostigmine. Anesthesiology 2008; 109(5): 816-24.
[http://dx.doi.org/10.1097/ALN.0b013e31818a3fee] [PMID: 18946293]
[26]
Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: Results of a randomised, controlled trial. Eur J Anaesthesiol 2010; 27(10): 874-81.
[http://dx.doi.org/10.1097/EJA.0b013e32833d56b7] [PMID: 20683334]
[27]
Illman HL, Laurila P, Antila H, Meretoja OA, Alahuhta S, Olkkola KT. The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring. Anesth Analg 2011; 112(1): 63-8.
[http://dx.doi.org/10.1213/ANE.0b013e3181fdf889] [PMID: 20978247]
[28]
Mraovic B, Timko NJ, Choma TJ. Comparison of recovery after sugammadex or neostigmine reversal of rocuronium in geriatric patients undergoing spine surgery: A randomized controlled trial. Croat Med J 2021; 62(6): 606-13.
[http://dx.doi.org/10.3325/cmj.2021.62.606] [PMID: 34981693]
[29]
Abdulatif M, Lotfy M, Mousa M, Afifi MH, Yassen K. Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: A randomized controlled study. Minerva Anestesiol 2018; 84(8): 929-37.
[http://dx.doi.org/10.23736/S0375-9393.18.12217-6] [PMID: 29405667]
[30]
Woo T, Kim KS, Shim YH, et al. Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients. Korean J Anesthesiol 2013; 65(6): 501-7.
[http://dx.doi.org/10.4097/kjae.2013.65.6.501] [PMID: 24427455]
[31]
Lemmens HJM, El-Orbany MI, Berry J, Morte JB Jr, Martin G. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: Sugammadex versus neostigmine. BMC Anesthesiol 2010; 10(1): 15.
[http://dx.doi.org/10.1186/1471-2253-10-15] [PMID: 20809967]
[32]
Ammar AS, Mahmoud KM, Kasemy ZA. A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. Acta Anaesthesiol Scand 2017; 61(4): 374-80.
[http://dx.doi.org/10.1111/aas.12868] [PMID: 28185260]
[33]
Ghoneim A, El Beltagy M. Comparative study between sugammadex and neostigmine in neurosurgical anesthesia in pediatric patients. Saudi J Anaesth 2015; 9(3): 247-52.
[http://dx.doi.org/10.4103/1658-354X.154696] [PMID: 26240540]
[34]
Kara T, Ozbagriacik O, Turk HS, et al. Sugammadex versus neostigmine in pediatric patients: A prospective randomized study Braz J Anesthesiol Engl Ed 2014; 64(6): 400-5.
[http://dx.doi.org/10.1016/j.bjane.2014.03.001]
[35]
Li L, Jiang Y, Zhang W. Sugammadex for fast-track surgery in children undergoing cardiac surgery: A randomized controlled study. J Cardiothorac Vasc Anesth 2021; 35(5): 1388-92.
[http://dx.doi.org/10.1053/j.jvca.2020.08.069] [PMID: 32962936]
[36]
Togioka BM, Yanez D, Aziz MF, Higgins JR, Tekkali P, Treggiari MM. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. Br J Anaesth 2020; 124(5): 553-61.
[http://dx.doi.org/10.1016/j.bja.2020.01.016] [PMID: 32139135]
[37]
Yağan Ö, Taş N, Mutlu T, Hancı V. Comparison of the effects of sugammadex and neostigmine on postoperative nausea and vomiting. Braz J Anesthesiol Elsevier 2017; 67(2): 147-52.
[38]
Ibrahim E. ELkhadry SW. Sugammadex versus neostigmine for reversal of rocuronium-induced neuromuscular blockade in infants: A prospective randomized pilot study. Perioper Care Oper Room Manag 2022; 26: 100224.
[http://dx.doi.org/10.1016/j.pcorm.2021.100224]
[39]
Korkmaz MO, Sayhan H, Guven M. Does sugammadex decrease the severity of agitation and complications in pediatric patients undergoing adenotonsillectomy? Saudi Med J 2019; 40(9): 907-13.
[http://dx.doi.org/10.15537/smj.2019.9.24485] [PMID: 31522218]
[40]
Ozgün C, Cakan T, Baltacı B, Başar H. Comparison of reversal and adverse effects of sugammadex and combination of - Anticholinergic-anticholinesterase agents in pediatric patients. J Res Med Sci 2014; 19(8): 762-8.
[PMID: 25422663]
[41]
Eikermann M, Vogt FM, Herbstreit F, et al. The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade. Am J Respir Crit Care Med 2007; 175(1): 9-15.
[http://dx.doi.org/10.1164/rccm.200512-1862OC] [PMID: 17023729]
[42]
Won YJ, Lim BG, Lee DK, Kim H, Kong MH, Lee IO. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients. Medicine 2016; 95(34): e4678.
[http://dx.doi.org/10.1097/MD.0000000000004678] [PMID: 27559972]
[43]
de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LHDJ. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: Reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth 2006; 96(2): 201-6.
[http://dx.doi.org/10.1093/bja/aei306] [PMID: 16377646]
[44]
Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: Pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology 2000; 92(4): 977-84.
[http://dx.doi.org/10.1097/00000542-200004000-00014] [PMID: 10754616]
[45]
Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: Simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 1997; 87(5): 1035-43.
[http://dx.doi.org/10.1097/00000542-199711000-00005] [PMID: 9366453]
[46]
Broens SJL, Boon M, Martini CH, et al. Reversal of partial neuromuscular block and the ventilatory response to hypoxia. Anesthesiology 2019; 131(3): 467-76.
[http://dx.doi.org/10.1097/ALN.0000000000002711] [PMID: 31045894]
[47]
Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex. Minerva Anestesiol 2016; 82(7): 735-42.
[PMID: 26472231]
[48]
Tramèr MR, Fuchs-Buder T. Omitting antagonism of neuromuscular block: Effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. Br J Anaesth 1999; 82(3): 379-86.
[http://dx.doi.org/10.1093/bja/82.3.379] [PMID: 10434820]
[49]
Krukowski JA, Hood DD, Eisenach JC, Mallak KA, Parker RL. Intrathecal neostigmine for post-cesarean section analgesia: Dose response. Anesth Analg 1997; 84(6): 1269-75.
[http://dx.doi.org/10.1213/00000539-199706000-00018] [PMID: 9174305]
[50]
Hood DD, Eisenach JC, Tuttle R. Phase I safety assessment of intrathecal neostigmine methylsulfate in humans. Anesthesiology 1995; 82(2): 331-43.
[http://dx.doi.org/10.1097/00000542-199502000-00003] [PMID: 7856891]
[51]
Meakin GH. Neuromuscular blocking drugs in infants and children. Contin Educ Anaesth Crit Care Pain 2007; 7(5): 143-7.
[http://dx.doi.org/10.1093/bjaceaccp/mkm032]
[52]
Ledowski T, Falke L, Johnston F, et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade. Eur J Anaesthesiol 2014; 31(8): 423-9.
[http://dx.doi.org/10.1097/EJA.0000000000000010] [PMID: 24296853]
[53]
Herbstreit F, Zigrahn D, Ochterbeck C, Peters J, Eikermann M. Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology 2010; 113(6): 1280-8.
[http://dx.doi.org/10.1097/ALN.0b013e3181f70f3d] [PMID: 20980910]
[54]
Caldwell JE. Clinical limitations of acetylcholinesterase antagonists. J Crit Care 2009; 24(1): 21-8.
[http://dx.doi.org/10.1016/j.jcrc.2008.08.003] [PMID: 19272535]
[55]
Carron M, Zarantonello F, Lazzarotto N, Tellaroli P, Ori C. Role of sugammadex in accelerating postoperative discharge: A meta-analysis. J Clin Anesth 2017; 39: 38-44.
[http://dx.doi.org/10.1016/j.jclinane.2017.03.004] [PMID: 28494905]

Rights & Permissions Print Cite
Article Metrics
45
2
© 2024 Bentham Science Publishers | Privacy Policy